Amy Shah
Concepts (368)
Concepts are derived automatically from a person's publications.
Concepts are listed by decreasing relevance which is based on many factors, including how many publications the person wrote about that topic, how long ago those publications were written, and how many publications other people have written on that same topic.
| Name |
Number of Publications
|
Most Recent Publication
|
Publications by All Authors
|
Concept Score
|
Why?
|
|---|
| Diabetes Mellitus, Type 2 | 67 | 2026 | 2623 | 9.890 |
Why?
| | Vascular Stiffness | 23 | 2025 | 488 | 6.310 |
Why?
| | Diabetes Mellitus, Type 1 | 45 | 2026 | 3930 | 4.230 |
Why?
| | Lipoproteins, HDL | 11 | 2025 | 104 | 3.370 |
Why?
| | Cardiovascular Diseases | 27 | 2025 | 2219 | 3.280 |
Why?
| | Pediatric Obesity | 13 | 2026 | 635 | 2.740 |
Why?
| | Adolescent | 101 | 2026 | 22557 | 2.440 |
Why?
| | Diabetic Angiopathies | 9 | 2025 | 265 | 2.170 |
Why?
| | Dyslipidemias | 10 | 2026 | 184 | 2.120 |
Why?
| | Bariatric Surgery | 6 | 2026 | 250 | 2.000 |
Why?
| | Apolipoprotein A-I | 9 | 2025 | 39 | 1.980 |
Why?
| | Pulse Wave Analysis | 20 | 2025 | 268 | 1.930 |
Why?
| | Blood Glucose | 14 | 2026 | 2360 | 1.830 |
Why?
| | Gastrectomy | 4 | 2026 | 164 | 1.800 |
Why?
| | Lipoproteins, LDL | 5 | 2025 | 119 | 1.670 |
Why?
| | Body Mass Index | 19 | 2026 | 2458 | 1.620 |
Why?
| | Carotid Intima-Media Thickness | 7 | 2020 | 75 | 1.580 |
Why?
| | Obesity, Morbid | 5 | 2024 | 287 | 1.550 |
Why?
| | Child | 71 | 2026 | 22693 | 1.540 |
Why?
| | Young Adult | 56 | 2026 | 14330 | 1.500 |
Why?
| | Lipoproteins | 6 | 2021 | 165 | 1.500 |
Why?
| | Obesity | 21 | 2026 | 3131 | 1.490 |
Why?
| | Prediabetic State | 3 | 2026 | 250 | 1.430 |
Why?
| | Endocrinology | 2 | 2024 | 77 | 1.350 |
Why?
| | Hypoglycemic Agents | 8 | 2026 | 1412 | 1.270 |
Why?
| | Risk Factors | 40 | 2026 | 10921 | 1.250 |
Why?
| | Gray Matter | 3 | 2025 | 96 | 1.240 |
Why?
| | Age of Onset | 12 | 2026 | 558 | 1.210 |
Why?
| | Humans | 134 | 2026 | 146342 | 1.170 |
Why?
| | Carotid Arteries | 7 | 2020 | 206 | 1.150 |
Why?
| | Cholesterol | 7 | 2024 | 411 | 1.080 |
Why?
| | Proteoglycans | 2 | 2025 | 111 | 1.060 |
Why?
| | Male | 86 | 2026 | 73396 | 1.020 |
Why?
| | Female | 85 | 2026 | 79499 | 0.980 |
Why?
| | Cross-Sectional Studies | 21 | 2025 | 5899 | 0.970 |
Why?
| | Diabetes Mellitus | 5 | 2026 | 1101 | 0.950 |
Why?
| | Atherosclerosis | 3 | 2024 | 410 | 0.920 |
Why?
| | Delayed Diagnosis | 1 | 2025 | 102 | 0.870 |
Why?
| | Heart Rate | 6 | 2022 | 846 | 0.840 |
Why?
| | Lipids | 8 | 2022 | 714 | 0.820 |
Why?
| | Gastroparesis | 1 | 2022 | 9 | 0.750 |
Why?
| | Weight Loss | 4 | 2026 | 858 | 0.750 |
Why?
| | Metabolic Syndrome | 1 | 2025 | 364 | 0.680 |
Why?
| | Adult | 36 | 2026 | 41087 | 0.670 |
Why?
| | Triglycerides | 7 | 2025 | 527 | 0.660 |
Why?
| | Apolipoproteins B | 2 | 2024 | 48 | 0.660 |
Why?
| | Disease Progression | 7 | 2026 | 2867 | 0.650 |
Why?
| | Hypertriglyceridemia | 3 | 2021 | 45 | 0.640 |
Why?
| | Hypertrophy, Left Ventricular | 1 | 2021 | 124 | 0.640 |
Why?
| | Autonomic Nervous System Diseases | 2 | 2019 | 38 | 0.620 |
Why?
| | Echocardiography | 2 | 2021 | 645 | 0.620 |
Why?
| | Gastric Bypass | 1 | 2021 | 115 | 0.610 |
Why?
| | Nervous System Diseases | 1 | 2023 | 288 | 0.610 |
Why?
| | Insulin Resistance | 7 | 2026 | 1247 | 0.590 |
Why?
| | Cholesterol, HDL | 6 | 2021 | 201 | 0.580 |
Why?
| | Ventricular Remodeling | 1 | 2021 | 283 | 0.570 |
Why?
| | Proteome | 4 | 2021 | 520 | 0.560 |
Why?
| | Prevalence | 10 | 2025 | 2861 | 0.560 |
Why?
| | Apolipoprotein A-II | 4 | 2024 | 5 | 0.550 |
Why?
| | Cardiomyopathies | 1 | 2022 | 340 | 0.530 |
Why?
| | Ventricular Dysfunction, Left | 1 | 2021 | 391 | 0.530 |
Why?
| | Ventricular Function, Left | 1 | 2021 | 541 | 0.520 |
Why?
| | Hypertension | 7 | 2025 | 1272 | 0.510 |
Why?
| | Atrial Fibrillation | 1 | 2023 | 560 | 0.490 |
Why?
| | White Matter | 1 | 2019 | 169 | 0.490 |
Why?
| | Arrhythmias, Cardiac | 1 | 2019 | 358 | 0.490 |
Why?
| | Cholesterol, LDL | 5 | 2024 | 363 | 0.470 |
Why?
| | Chemical Precipitation | 1 | 2016 | 39 | 0.470 |
Why?
| | Ohio | 5 | 2016 | 136 | 0.470 |
Why?
| | Metabolic Diseases | 1 | 2017 | 114 | 0.470 |
Why?
| | Executive Function | 2 | 2019 | 463 | 0.430 |
Why?
| | Cohort Studies | 13 | 2025 | 6077 | 0.420 |
Why?
| | Pediatrics | 2 | 2020 | 1124 | 0.420 |
Why?
| | Cognitive Dysfunction | 3 | 2023 | 481 | 0.420 |
Why?
| | Problem Behavior | 1 | 2016 | 97 | 0.420 |
Why?
| | Quinolines | 2 | 2026 | 191 | 0.420 |
Why?
| | Arteries | 1 | 2016 | 261 | 0.410 |
Why?
| | Phosphatidylcholine-Sterol O-Acyltransferase | 3 | 2025 | 8 | 0.400 |
Why?
| | Vasculitis | 1 | 2014 | 69 | 0.400 |
Why?
| | Vasodilation | 1 | 2017 | 519 | 0.400 |
Why?
| | Peripheral Vascular Diseases | 1 | 2014 | 102 | 0.390 |
Why?
| | Case-Control Studies | 8 | 2021 | 3647 | 0.390 |
Why?
| | Microvessels | 1 | 2014 | 98 | 0.380 |
Why?
| | Vitamin D Deficiency | 1 | 2015 | 189 | 0.380 |
Why?
| | Adiposity | 2 | 2015 | 533 | 0.380 |
Why?
| | Albuminuria | 3 | 2025 | 190 | 0.380 |
Why?
| | Follow-Up Studies | 10 | 2026 | 5439 | 0.370 |
Why?
| | Vascular Resistance | 1 | 2014 | 365 | 0.360 |
Why?
| | Sphygmomanometers | 1 | 2012 | 7 | 0.360 |
Why?
| | Prospective Studies | 7 | 2026 | 8123 | 0.360 |
Why?
| | Pancreatitis | 3 | 2026 | 146 | 0.360 |
Why?
| | Pilot Projects | 5 | 2025 | 1888 | 0.360 |
Why?
| | Mercury | 1 | 2012 | 41 | 0.350 |
Why?
| | Vitamin D | 1 | 2015 | 402 | 0.340 |
Why?
| | Hydroxymethylglutaryl-CoA Reductase Inhibitors | 3 | 2026 | 449 | 0.340 |
Why?
| | Endothelium, Vascular | 2 | 2017 | 952 | 0.340 |
Why?
| | Age Factors | 8 | 2020 | 3347 | 0.340 |
Why?
| | Diastole | 2 | 2022 | 147 | 0.340 |
Why?
| | Blood Pressure Determination | 1 | 2012 | 143 | 0.330 |
Why?
| | Adolescent Behavior | 1 | 2016 | 486 | 0.330 |
Why?
| | Cerebrovascular Circulation | 2 | 2025 | 293 | 0.330 |
Why?
| | Carotid Artery, Internal | 1 | 2011 | 45 | 0.320 |
Why?
| | Biomarkers | 9 | 2026 | 4340 | 0.320 |
Why?
| | Feeding Behavior | 3 | 2025 | 692 | 0.320 |
Why?
| | C-Peptide | 3 | 2026 | 191 | 0.310 |
Why?
| | Treatment Outcome | 6 | 2026 | 11821 | 0.310 |
Why?
| | Insulin | 5 | 2026 | 2525 | 0.310 |
Why?
| | Protein Binding | 3 | 2025 | 2244 | 0.310 |
Why?
| | Adiponectin | 1 | 2012 | 243 | 0.310 |
Why?
| | Early Diagnosis | 2 | 2025 | 251 | 0.300 |
Why?
| | Genetic Predisposition to Disease | 4 | 2021 | 2488 | 0.290 |
Why?
| | Blood Pressure | 6 | 2015 | 1765 | 0.290 |
Why?
| | Lipid Metabolism | 1 | 2013 | 533 | 0.290 |
Why?
| | Particle Size | 4 | 2021 | 386 | 0.280 |
Why?
| | Proprotein Convertase 9 | 2 | 2020 | 88 | 0.280 |
Why?
| | Incidence | 5 | 2024 | 2936 | 0.270 |
Why?
| | Heart Failure | 1 | 2022 | 2329 | 0.270 |
Why?
| | Heart | 2 | 2023 | 626 | 0.260 |
Why?
| | Mass Spectrometry | 6 | 2019 | 729 | 0.260 |
Why?
| | Smoking | 1 | 2014 | 1486 | 0.240 |
Why?
| | Pancreas, Exocrine | 1 | 2026 | 7 | 0.240 |
Why?
| | Overweight | 2 | 2026 | 614 | 0.230 |
Why?
| | Exocrine Pancreatic Insufficiency | 1 | 2026 | 25 | 0.230 |
Why?
| | Apolipoprotein A-V | 1 | 2025 | 4 | 0.230 |
Why?
| | Lipoproteins, VLDL | 1 | 2025 | 21 | 0.230 |
Why?
| | Retrospective Studies | 10 | 2026 | 17438 | 0.230 |
Why?
| | ATP Binding Cassette Transporter 1 | 3 | 2024 | 13 | 0.230 |
Why?
| | Biological Transport | 4 | 2024 | 424 | 0.220 |
Why?
| | Brain | 3 | 2025 | 2991 | 0.220 |
Why?
| | Apolipoproteins E | 1 | 2025 | 97 | 0.220 |
Why?
| | Food Assistance | 1 | 2025 | 34 | 0.220 |
Why?
| | Pancreatitis, Chronic | 1 | 2025 | 64 | 0.210 |
Why?
| | Dietary Carbohydrates | 1 | 2025 | 146 | 0.210 |
Why?
| | Magnetic Resonance Imaging | 4 | 2025 | 3926 | 0.210 |
Why?
| | Multiple Endocrine Neoplasia Type 1 | 1 | 2024 | 2 | 0.210 |
Why?
| | Insulinoma | 1 | 2024 | 30 | 0.200 |
Why?
| | Pregnancy in Diabetics | 1 | 2026 | 123 | 0.200 |
Why?
| | Risk Assessment | 4 | 2021 | 3712 | 0.200 |
Why?
| | Preoperative Period | 1 | 2024 | 157 | 0.200 |
Why?
| | United States | 11 | 2026 | 16136 | 0.190 |
Why?
| | Insulin Glargine | 1 | 2023 | 88 | 0.190 |
Why?
| | Longitudinal Studies | 5 | 2023 | 3017 | 0.190 |
Why?
| | Pharmacy | 1 | 2023 | 32 | 0.190 |
Why?
| | Extracellular Vesicles | 1 | 2025 | 176 | 0.180 |
Why?
| | Mass Screening | 3 | 2022 | 1307 | 0.180 |
Why?
| | Mice | 7 | 2025 | 18297 | 0.180 |
Why?
| | Pandemics | 4 | 2026 | 1707 | 0.180 |
Why?
| | Sex Factors | 3 | 2015 | 2107 | 0.180 |
Why?
| | Diabetic Neuropathies | 2 | 2023 | 101 | 0.180 |
Why?
| | Proteomics | 4 | 2021 | 1203 | 0.180 |
Why?
| | Lipid Metabolism Disorders | 1 | 2021 | 4 | 0.180 |
Why?
| | Off-Label Use | 1 | 2022 | 50 | 0.170 |
Why?
| | Diabetic Nephropathies | 3 | 2020 | 320 | 0.170 |
Why?
| | Meta-Analysis as Topic | 1 | 2022 | 173 | 0.170 |
Why?
| | Receptors, CXCR3 | 1 | 2021 | 17 | 0.170 |
Why?
| | Pyruvate Kinase | 1 | 2021 | 29 | 0.170 |
Why?
| | Radiation Oncology | 1 | 2022 | 83 | 0.170 |
Why?
| | Sleep Apnea, Obstructive | 1 | 2025 | 300 | 0.170 |
Why?
| | Thyroid Hormones | 1 | 2021 | 69 | 0.160 |
Why?
| | Autoantibodies | 2 | 2025 | 1500 | 0.160 |
Why?
| | Lipoprotein(a) | 1 | 2021 | 70 | 0.160 |
Why?
| | Quantitative Trait, Heritable | 1 | 2021 | 119 | 0.160 |
Why?
| | Insulin-Secreting Cells | 1 | 2025 | 393 | 0.160 |
Why?
| | Regression Analysis | 2 | 2014 | 999 | 0.160 |
Why?
| | Animals | 9 | 2025 | 38107 | 0.160 |
Why?
| | Cognition | 3 | 2023 | 1292 | 0.160 |
Why?
| | Th17 Cells | 1 | 2021 | 103 | 0.160 |
Why?
| | Chromosome Mapping | 1 | 2021 | 508 | 0.150 |
Why?
| | Drug Chronotherapy | 1 | 2019 | 2 | 0.150 |
Why?
| | Turner Syndrome | 1 | 2020 | 61 | 0.150 |
Why?
| | Diabetic Ketoacidosis | 1 | 2022 | 212 | 0.150 |
Why?
| | Radiology | 1 | 2022 | 175 | 0.150 |
Why?
| | Prenatal Exposure Delayed Effects | 1 | 2026 | 665 | 0.150 |
Why?
| | Cell Adhesion Molecules | 1 | 2020 | 180 | 0.150 |
Why?
| | Research | 1 | 2022 | 421 | 0.140 |
Why?
| | Autonomic Nervous System | 1 | 2019 | 82 | 0.140 |
Why?
| | Neurology | 1 | 2020 | 107 | 0.140 |
Why?
| | Randomized Controlled Trials as Topic | 2 | 2025 | 1763 | 0.140 |
Why?
| | Kidney Diseases | 1 | 2023 | 428 | 0.140 |
Why?
| | Islets of Langerhans | 1 | 2025 | 852 | 0.140 |
Why?
| | Oxidation-Reduction | 3 | 2018 | 1075 | 0.140 |
Why?
| | Stroke Volume | 1 | 2022 | 652 | 0.140 |
Why?
| | Multivariate Analysis | 3 | 2017 | 1543 | 0.140 |
Why?
| | Hypolipidemic Agents | 1 | 2019 | 89 | 0.140 |
Why?
| | Shock, Septic | 1 | 2020 | 230 | 0.130 |
Why?
| | Non-alcoholic Fatty Liver Disease | 1 | 2021 | 265 | 0.130 |
Why?
| | Alleles | 1 | 2021 | 907 | 0.130 |
Why?
| | Predictive Value of Tests | 2 | 2021 | 2113 | 0.130 |
Why?
| | Blood Chemical Analysis | 1 | 2018 | 109 | 0.130 |
Why?
| | Weight Reduction Programs | 1 | 2019 | 140 | 0.130 |
Why?
| | Vascular Diseases | 1 | 2020 | 252 | 0.130 |
Why?
| | Physicians, Primary Care | 1 | 2020 | 210 | 0.130 |
Why?
| | Anticonvulsants | 1 | 2020 | 253 | 0.130 |
Why?
| | Dwarfism, Pituitary | 1 | 2017 | 2 | 0.130 |
Why?
| | Pharmaceutical Preparations | 1 | 2019 | 172 | 0.130 |
Why?
| | Drug Administration Schedule | 1 | 2019 | 790 | 0.130 |
Why?
| | Parenting | 1 | 2021 | 309 | 0.130 |
Why?
| | Mentoring | 1 | 2020 | 166 | 0.130 |
Why?
| | Prognosis | 5 | 2026 | 4351 | 0.130 |
Why?
| | Linear Models | 4 | 2015 | 857 | 0.130 |
Why?
| | Phenotype | 2 | 2026 | 3206 | 0.130 |
Why?
| | Cluster Analysis | 2 | 2026 | 496 | 0.130 |
Why?
| | Combined Modality Therapy | 2 | 2020 | 1271 | 0.130 |
Why?
| | Human Growth Hormone | 1 | 2017 | 46 | 0.120 |
Why?
| | Carrier Proteins | 1 | 2021 | 728 | 0.120 |
Why?
| | Algorithms | 1 | 2024 | 1849 | 0.120 |
Why?
| | Pneumonia, Viral | 1 | 2022 | 387 | 0.120 |
Why?
| | Apolipoproteins | 1 | 2016 | 38 | 0.120 |
Why?
| | Memory | 1 | 2019 | 298 | 0.120 |
Why?
| | Manganese Compounds | 1 | 2016 | 4 | 0.120 |
Why?
| | Polymorphism, Single Nucleotide | 2 | 2021 | 2240 | 0.120 |
Why?
| | Fatty Acids, Unsaturated | 1 | 2016 | 97 | 0.120 |
Why?
| | Practice Guidelines as Topic | 1 | 2024 | 1591 | 0.120 |
Why?
| | Genetic Variation | 1 | 2021 | 996 | 0.120 |
Why?
| | Dextran Sulfate | 1 | 2016 | 93 | 0.110 |
Why?
| | Genomics | 1 | 2021 | 853 | 0.110 |
Why?
| | Verbal Learning | 1 | 2016 | 75 | 0.110 |
Why?
| | Outpatient Clinics, Hospital | 1 | 2016 | 80 | 0.110 |
Why?
| | Logistic Models | 2 | 2020 | 2126 | 0.110 |
Why?
| | Influenza, Human | 1 | 2022 | 640 | 0.110 |
Why?
| | Epilepsy | 1 | 2020 | 400 | 0.110 |
Why?
| | Carotid Artery Diseases | 1 | 2015 | 70 | 0.110 |
Why?
| | Hyperlipoproteinemia Type III | 1 | 2015 | 4 | 0.110 |
Why?
| | Pancreatic Neoplasms | 1 | 2024 | 944 | 0.110 |
Why?
| | Hyperlipoproteinemia Type I | 1 | 2015 | 7 | 0.110 |
Why?
| | Remission Induction | 1 | 2016 | 308 | 0.110 |
Why?
| | Colorado | 2 | 2015 | 4595 | 0.110 |
Why?
| | Attention | 1 | 2019 | 463 | 0.110 |
Why?
| | Chlorides | 1 | 2016 | 138 | 0.110 |
Why?
| | Ankle Brachial Index | 1 | 2015 | 41 | 0.110 |
Why?
| | Phosphoproteins | 1 | 2017 | 320 | 0.110 |
Why?
| | Gene Deletion | 1 | 2016 | 385 | 0.110 |
Why?
| | Membrane Proteins | 1 | 2021 | 1130 | 0.110 |
Why?
| | Diet | 2 | 2020 | 1273 | 0.110 |
Why?
| | Asymptomatic Diseases | 1 | 2015 | 102 | 0.110 |
Why?
| | Laser-Doppler Flowmetry | 1 | 2014 | 31 | 0.100 |
Why?
| | Heparin | 1 | 2016 | 247 | 0.100 |
Why?
| | Brain Concussion | 1 | 2022 | 660 | 0.100 |
Why?
| | Curriculum | 1 | 2021 | 1079 | 0.100 |
Why?
| | Forearm | 1 | 2014 | 141 | 0.100 |
Why?
| | Comorbidity | 3 | 2025 | 1665 | 0.100 |
Why?
| | Dietary Fiber | 1 | 2014 | 59 | 0.100 |
Why?
| | Vascular Remodeling | 1 | 2015 | 208 | 0.100 |
Why?
| | Memory, Short-Term | 1 | 2016 | 276 | 0.100 |
Why?
| | Magnetic Resonance Spectroscopy | 1 | 2016 | 627 | 0.100 |
Why?
| | Nutrition Therapy | 1 | 2013 | 37 | 0.090 |
Why?
| | Exercise | 2 | 2022 | 2213 | 0.090 |
Why?
| | American Heart Association | 1 | 2014 | 364 | 0.090 |
Why?
| | Comparative Effectiveness Research | 1 | 2013 | 171 | 0.090 |
Why?
| | Analysis of Variance | 1 | 2015 | 1298 | 0.090 |
Why?
| | Fructose | 1 | 2013 | 132 | 0.090 |
Why?
| | Hospitals, Pediatric | 1 | 2016 | 561 | 0.090 |
Why?
| | Regional Blood Flow | 1 | 2014 | 507 | 0.090 |
Why?
| | Hyperglycemia | 1 | 2016 | 384 | 0.090 |
Why?
| | Life Style | 3 | 2022 | 496 | 0.090 |
Why?
| | Glucose | 1 | 2017 | 1053 | 0.090 |
Why?
| | Child, Preschool | 6 | 2026 | 11913 | 0.090 |
Why?
| | Hot Temperature | 1 | 2014 | 396 | 0.080 |
Why?
| | Quality Improvement | 1 | 2020 | 1354 | 0.080 |
Why?
| | Inservice Training | 1 | 2012 | 115 | 0.080 |
Why?
| | Observer Variation | 1 | 2012 | 356 | 0.080 |
Why?
| | Osteoarthritis | 1 | 2013 | 206 | 0.080 |
Why?
| | Polyethylene Glycols | 1 | 2016 | 650 | 0.080 |
Why?
| | Double-Blind Method | 2 | 2026 | 2070 | 0.080 |
Why?
| | Time Factors | 4 | 2020 | 7109 | 0.080 |
Why?
| | Adaptation, Psychological | 1 | 2016 | 721 | 0.080 |
Why?
| | Femoral Artery | 1 | 2011 | 183 | 0.080 |
Why?
| | Heart Ventricles | 1 | 2015 | 762 | 0.080 |
Why?
| | Mice, Inbred C57BL | 4 | 2025 | 6034 | 0.080 |
Why?
| | Tunica Media | 1 | 2009 | 39 | 0.070 |
Why?
| | Primary Health Care | 1 | 2020 | 1776 | 0.070 |
Why?
| | Skin | 1 | 2014 | 701 | 0.070 |
Why?
| | Tunica Intima | 1 | 2009 | 80 | 0.070 |
Why?
| | Glomerular Filtration Rate | 2 | 2023 | 745 | 0.060 |
Why?
| | Feasibility Studies | 2 | 2025 | 1135 | 0.060 |
Why?
| | Guideline Adherence | 1 | 2012 | 594 | 0.060 |
Why?
| | Research Design | 1 | 2013 | 1143 | 0.060 |
Why?
| | Drug Therapy, Combination | 2 | 2020 | 1036 | 0.060 |
Why?
| | Chromatography, Gel | 2 | 2017 | 131 | 0.060 |
Why?
| | Hemodynamics | 1 | 2012 | 1114 | 0.060 |
Why?
| | Mice, Knockout | 2 | 2025 | 3125 | 0.060 |
Why?
| | Metformin | 2 | 2020 | 328 | 0.060 |
Why?
| | Peptide YY | 1 | 2026 | 28 | 0.060 |
Why?
| | Resistin | 1 | 2025 | 12 | 0.060 |
Why?
| | Cameroon | 1 | 2025 | 8 | 0.060 |
Why?
| | Pregnancy Trimester, First | 1 | 2026 | 140 | 0.060 |
Why?
| | Africa South of the Sahara | 1 | 2025 | 56 | 0.060 |
Why?
| | Glucose Tolerance Test | 1 | 2026 | 360 | 0.050 |
Why?
| | Molecular Docking Simulation | 1 | 2025 | 121 | 0.050 |
Why?
| | Glucagon-Like Peptide 1 | 1 | 2026 | 150 | 0.050 |
Why?
| | Hepatocytes | 1 | 2025 | 224 | 0.050 |
Why?
| | South Africa | 1 | 2025 | 262 | 0.050 |
Why?
| | Polysomnography | 1 | 2025 | 239 | 0.050 |
Why?
| | Multicenter Studies as Topic | 1 | 2025 | 417 | 0.050 |
Why?
| | Leptin | 1 | 2025 | 248 | 0.050 |
Why?
| | Reproducibility of Results | 1 | 2012 | 3416 | 0.050 |
Why?
| | Goals | 1 | 2025 | 187 | 0.050 |
Why?
| | Patient Education as Topic | 2 | 2020 | 770 | 0.040 |
Why?
| | Inflammation | 1 | 2014 | 2919 | 0.040 |
Why?
| | Aged | 5 | 2021 | 26432 | 0.040 |
Why?
| | Family Characteristics | 1 | 2023 | 203 | 0.040 |
Why?
| | Body Composition | 1 | 2026 | 689 | 0.040 |
Why?
| | Binding Sites | 1 | 2025 | 1309 | 0.040 |
Why?
| | Diabetes Complications | 1 | 2023 | 219 | 0.040 |
Why?
| | Mendelian Randomization Analysis | 1 | 2021 | 68 | 0.040 |
Why?
| | Middle Aged | 5 | 2023 | 36619 | 0.040 |
Why?
| | Adipose Tissue | 1 | 2025 | 642 | 0.040 |
Why?
| | Sitosterols | 1 | 2020 | 2 | 0.040 |
Why?
| | Infant | 3 | 2023 | 10114 | 0.040 |
Why?
| | Protein Interaction Mapping | 1 | 2021 | 105 | 0.040 |
Why?
| | Minority Groups | 1 | 2023 | 286 | 0.040 |
Why?
| | Phytosterols | 1 | 2020 | 10 | 0.040 |
Why?
| | Phospholipids | 1 | 2022 | 215 | 0.040 |
Why?
| | Organ Dysfunction Scores | 1 | 2020 | 55 | 0.040 |
Why?
| | United Kingdom | 1 | 2021 | 377 | 0.040 |
Why?
| | Drug Discovery | 1 | 2021 | 154 | 0.040 |
Why?
| | Videoconferencing | 1 | 2020 | 62 | 0.040 |
Why?
| | Radiography | 1 | 2022 | 861 | 0.040 |
Why?
| | Schools | 1 | 2022 | 436 | 0.040 |
Why?
| | Anthropometry | 1 | 2019 | 204 | 0.040 |
Why?
| | Risk Reduction Behavior | 1 | 2020 | 220 | 0.030 |
Why?
| | Transition to Adult Care | 1 | 2020 | 111 | 0.030 |
Why?
| | Safety | 1 | 2020 | 347 | 0.030 |
Why?
| | Enzyme-Linked Immunosorbent Assay | 1 | 2020 | 846 | 0.030 |
Why?
| | Documentation | 1 | 2020 | 202 | 0.030 |
Why?
| | Learning | 1 | 2022 | 446 | 0.030 |
Why?
| | Molecular Targeted Therapy | 1 | 2021 | 447 | 0.030 |
Why?
| | Intensive Care Units, Pediatric | 1 | 2020 | 293 | 0.030 |
Why?
| | Diabetic Retinopathy | 1 | 2020 | 211 | 0.030 |
Why?
| | Inflammation Mediators | 1 | 2020 | 508 | 0.030 |
Why?
| | Focus Groups | 1 | 2020 | 588 | 0.030 |
Why?
| | RNA, Messenger | 1 | 2025 | 2791 | 0.030 |
Why?
| | Counseling | 1 | 2020 | 406 | 0.030 |
Why?
| | Liver | 1 | 2025 | 1864 | 0.030 |
Why?
| | Fasting | 1 | 2018 | 280 | 0.030 |
Why?
| | Students | 1 | 2022 | 649 | 0.030 |
Why?
| | Self Efficacy | 1 | 2020 | 418 | 0.030 |
Why?
| | Enzyme Activation | 1 | 2018 | 759 | 0.030 |
Why?
| | Ultrasonography | 1 | 2020 | 788 | 0.030 |
Why?
| | Apolipoproteins A | 1 | 2016 | 19 | 0.030 |
Why?
| | Mutation | 2 | 2018 | 4093 | 0.030 |
Why?
| | Gene Expression | 1 | 2021 | 1463 | 0.030 |
Why?
| | Healthy Volunteers | 1 | 2017 | 218 | 0.030 |
Why?
| | Disease Management | 1 | 2020 | 651 | 0.030 |
Why?
| | Pedigree | 1 | 2017 | 512 | 0.030 |
Why?
| | Societies, Medical | 1 | 2020 | 907 | 0.030 |
Why?
| | Self Report | 1 | 2020 | 870 | 0.030 |
Why?
| | Cell Line | 1 | 2021 | 2814 | 0.030 |
Why?
| | Autoimmunity | 1 | 2021 | 925 | 0.030 |
Why?
| | Nutrition Surveys | 1 | 2016 | 270 | 0.030 |
Why?
| | Chi-Square Distribution | 1 | 2015 | 517 | 0.030 |
Why?
| | CD4-Positive T-Lymphocytes | 1 | 2021 | 1150 | 0.030 |
Why?
| | Spectrometry, Mass, Electrospray Ionization | 1 | 2015 | 175 | 0.030 |
Why?
| | Hospitals | 1 | 2019 | 738 | 0.030 |
Why?
| | Body Weights and Measures | 1 | 2013 | 37 | 0.030 |
Why?
| | Referral and Consultation | 1 | 2020 | 881 | 0.030 |
Why?
| | Models, Chemical | 1 | 2015 | 252 | 0.020 |
Why?
| | Chromatography, High Pressure Liquid | 1 | 2015 | 588 | 0.020 |
Why?
| | Pregnancy | 1 | 2026 | 7230 | 0.020 |
Why?
| | Fibrinogen | 1 | 2014 | 182 | 0.020 |
Why?
| | Parents | 1 | 2021 | 1394 | 0.020 |
Why?
| | Clinical Competence | 1 | 2020 | 1272 | 0.020 |
Why?
| | Mental Disorders | 1 | 2020 | 1148 | 0.020 |
Why?
| | Sex Characteristics | 1 | 2017 | 801 | 0.020 |
Why?
| | Registries | 1 | 2018 | 2400 | 0.020 |
Why?
| | Aged, 80 and over | 1 | 2021 | 8391 | 0.020 |
Why?
| | Exercise Therapy | 1 | 2013 | 488 | 0.020 |
Why?
| | Health Behavior | 1 | 2013 | 802 | 0.020 |
Why?
|
|
Shah's Networks
Click the "See All" links for more information and interactive visualizations!
Concepts  Derived automatically from this person's publications. _
Co-Authors  People in Profiles who have published with this person. _
Similar People  People who share similar concepts with this person. _
Same Department
People who are also in this person's primary department.
|